{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:30:22Z","timestamp":1794591022310,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A2B6005559"],"award-info":[{"award-number":["NRF-2018R1A2B6005559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The immune microenvironment in ductal carcinoma in situ (DCIS) and its significance are not well established. This study was conducted to evaluate the immune microenvironment of DCIS including the composition of tumor-infiltrating lymphocyte (TIL) subsets and PD-L1+ immune cells and to compare it with that of invasive breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>A total of 671 cases including three different disease groups of pure DCIS, DCIS with microinvasion (DCIS-M), and invasive carcinoma were included in this study. CD4+, CD8+, and FOXP3+ TIL subsets and PD-L1+ immune cells were detected with immunohistochemistry using tissue microarrays and were analyzed in relation to clinicopathologic characteristics and different disease groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In pure DCIS, high infiltrations of CD4+, CD8+, and FOXP3+ T cells and the presence of PD-L1+ immune cells were associated with high nuclear grade, comedo-type necrosis, hormone receptor (HR) negativity, and high Ki-67 proliferation index. All immune cell infiltrations were higher in invasive carcinoma than in pure DCIS regardless of the HR status. While CD4+ T cells were more abundant than CD8+ T cells in pure DCIS, CD8+ T cells were dominant in invasive carcinoma, especially in HR-negative tumors. Within individual cases of invasive carcinoma with DCIS component, all immune cell subset infiltration was higher in the invasive component than in the DCIS component; however, CD4+ TIL infiltration did not differ between the two components in HR-negative tumors. Comparing pure DCIS, DCIS-M, and DCIS associated with invasive carcinoma (DCIS-INV), CD4+ TIL infiltration revealed a gradual increase from pure DCIS to DCIS-M and DCIS-INV in the HR-negative group, whereas FOXP3+ TIL infiltration was significantly increased in DCIS-INV than in pure DCIS in the HR-positive group. The high infiltration of FOXP3+ TIL and the presence of PD-L1+ immune cells were associated with tumor recurrence in patients with pure DCIS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study showed that the immune microenvironment differs significantly not only between DCIS and invasive carcinoma but also between pure DCIS, DCIS-M, and DCIS-INV depending on the HR status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-020-01267-w","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T09:03:12Z","timestamp":1585213392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast"],"prefix":"10.1186","volume":"22","author":[{"given":"Milim","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yul Ri","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soomin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"issue":"2","key":"1267_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-015-3472-6","volume":"152","author":"VC Koh","year":"2015","unstructured":"Koh VC, Lim JC, Thike AA, Cheok PY, Thu MM, Tan VK, Tan BK, Ong KW, Ho GH, Tan WJ, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152(2):293\u2013304.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1267_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-005-9101-z","volume":"97","author":"B Erbas","year":"2006","unstructured":"Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135\u201344.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1267_CR3","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1016\/j.humpath.2013.07.003","volume":"44","author":"Y Choi","year":"2013","unstructured":"Choi Y, Lee HJ, Jang MH, Gwak JM, Lee KS, Kim EJ, Kim HJ, Lee HE, Park SY. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer. Hum Pathol. 2013;44(11):2581\u20139.","journal-title":"Hum Pathol"},{"issue":"5","key":"1267_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137\u201346.","journal-title":"J Clin Invest"},{"key":"1267_CR5","doi-asserted-by":"crossref","unstructured":"Chen XY, Yeong J, Thike AA, Bay BH, Tan PH. Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treatment 2019;177(1):17\u201327.","DOI":"10.1007\/s10549-019-05272-2"},{"issue":"10","key":"1267_CR6","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.3944","volume":"21","author":"G Kroemer","year":"2015","unstructured":"Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128\u201338.","journal-title":"Nat Med"},{"key":"1267_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","volume":"29","author":"S Luen","year":"2016","unstructured":"Luen S, Virassamy B, Savas P, Salgado R, Loi S. The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016;29:241\u201350.","journal-title":"Breast"},{"issue":"7528","key":"1267_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"1","key":"1267_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","volume":"28","author":"C Denkert","year":"2010","unstructured":"Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105\u201313.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1267_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","volume":"31","author":"S Loi","year":"2013","unstructured":"Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1267_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/bjc.2012.347","volume":"107","author":"ZM Mohammed","year":"2012","unstructured":"Mohammed ZM, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012;107(5):864\u201373.","journal-title":"Br J Cancer"},{"issue":"15","key":"1267_CR12","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","volume":"29","author":"SM Mahmoud","year":"2011","unstructured":"Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949\u201355.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1267_CR13","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/bjc.2013.634","volume":"109","author":"AN Seo","year":"2013","unstructured":"Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705\u201313.","journal-title":"Br J Cancer"},{"issue":"3","key":"1267_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-016-4072-9","volume":"161","author":"YR Chung","year":"2017","unstructured":"Chung YR, Kim HJ, Jang MH, Park SY. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017;161(3):409\u201320.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1267_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, Aneja R, Green AR, Ellis IO, Rakha EA. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Modern Pathol. 2018;31(8):1226\u201336.","journal-title":"Modern Pathol"},{"issue":"17","key":"1267_CR16","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res. 2017;23(17):5210\u20137.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1267_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2017","unstructured":"Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017;161(1):17\u201328.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1267_CR18","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71(2):258\u201368.","journal-title":"Histopathology"},{"issue":"10","key":"1267_CR19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1218106","volume":"5","author":"M Semeraro","year":"2016","unstructured":"Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, et al. The ratio of CD8(+)\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 2016;5(10):e1218106.","journal-title":"Oncoimmunology"},{"issue":"3","key":"1267_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/modpathol.2015.158","volume":"29","author":"E Thompson","year":"2016","unstructured":"Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Modern Pathol. 2016;29(3):249\u201358.","journal-title":"Modern Pathol"},{"issue":"2","key":"1267_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/ajcp\/aqz020","volume":"152","author":"JM Ubago","year":"2019","unstructured":"Ubago JM, Blanco LZ, Shen T, Siziopikou KP. The PD-1\/PD-L1 axis in HER2+ ductal carcinoma in situ (DCIS) of the breast. Am J Clin Pathol. 2019;152(2):169\u201376.","journal-title":"Am J Clin Pathol"},{"key":"1267_CR22","doi-asserted-by":"crossref","unstructured":"Lv S, Wang S, Qiao G, Wang X, Zhou X, Yan F, Li Y, Wang S, Morse MA, Hobeika A, et al. Functional CD3(+)CD8(+)PD1(\u2212) T cell accumulation and PD-L1 expression increases during tumor invasion in DCIS of the breast. Clin Breast Cancer. 2019;19(5):e617\u2013e623.","DOI":"10.1016\/j.clbc.2019.04.001"},{"issue":"5","key":"1267_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anatomic Pathol. 2017;24(5):235\u201351.","journal-title":"Adv Anatomic Pathol"},{"issue":"Pt 2","key":"1267_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on breast cancer. Semin Cancer Biol. 2018;52(Pt 2):16\u201325.","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"1267_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354\u201360.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1267_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Annals Oncol. 2017;28(2):321\u20138.","journal-title":"Annals Oncol"},{"issue":"1","key":"1267_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12885-018-4013-6","volume":"18","author":"M Beguinot","year":"2018","unstructured":"Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, Penault-Llorca F, Radosevic-Robin N. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 2018;18(1):129.","journal-title":"BMC Cancer"},{"issue":"9","key":"1267_CR28","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/jcp.2005.031252","volume":"59","author":"MR Hussein","year":"2006","unstructured":"Hussein MR, Hassan HI. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations. J Clin Pathol. 2006;59(9):972\u20137.","journal-title":"J Clin Pathol"},{"issue":"2","key":"1267_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-013-2556-4","volume":"139","author":"A Lal","year":"2013","unstructured":"Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"1267_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2(2):91\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1267_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13058-018-0942-x","volume":"20","author":"M Schmidt","year":"2018","unstructured":"Schmidt M, Weyer-Elberich V, Hengstler JG, Heimes AS, Almstedt K, Gerhold-Ay A, Lebrecht A, Battista MJ, Hasenburg A, Sahin U, et al. Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Res. 2018;20(1):15.","journal-title":"Breast Cancer Res"},{"issue":"Pt 2","key":"1267_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","volume":"52","author":"D Hammerl","year":"2018","unstructured":"Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol. 2018;52(Pt 2):178\u201388.","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1267_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s13058-014-0432-8","volume":"16","author":"S Liu","year":"2014","unstructured":"Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"1267_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1055\/s-2007-1003570","volume":"12","author":"RH Goldfarb","year":"1986","unstructured":"Goldfarb RH, Liotta LA. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost. 1986;12(4):294\u2013307.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"1267_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10911-005-9584-6","volume":"10","author":"K Polyak","year":"2005","unstructured":"Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia. 2005;10(3):231\u201347.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"2","key":"1267_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.yexcr.2004.08.037","volume":"301","author":"YG Man","year":"2004","unstructured":"Man YG, Sang QX. The significance of focal myoepithelial cell layer disruptions in human breast tumor invasion: a paradigm shift from the \u201cprotease-centered\u201d hypothesis. Exp Cell Res. 2004;301(2):103\u201318.","journal-title":"Exp Cell Res"},{"issue":"15","key":"1267_CR37","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1158\/1078-0432.CCR-04-0165","volume":"10","author":"ES Hwang","year":"2004","unstructured":"Hwang ES, DeVries S, Chew KL, Moore DH 2nd, Kerlikowske K, Thor A, Ljung BM, Waldman FM. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10(15):5160\u20137.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1267_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.breast.2008.06.001","volume":"17","author":"BC Sheu","year":"2008","unstructured":"Sheu BC, Kuo WH, Chen RJ, Huang SC, Chang KJ, Chow SN. Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer. Breast. 2008;17(6):604\u201310.","journal-title":"Breast"},{"issue":"10","key":"1267_CR39","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discovery. 2017;7(10):1098\u2013115.","journal-title":"Cancer Discovery"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-020-01267-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01267-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:29:12Z","timestamp":1616718552000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01267-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1267"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01267-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"18 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (IRB No B-1803\/450-305), and informed consent was waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}